Drug intelligence / Profile preview

JTT-302

Development stage: Phase 2
Lead developer: Japan Tobacco
Modality: Small Molecules
Administration: Oral

Overview

JTT-302 is an investigational small molecule drug developed as an oral inhibitor of cholesteryl ester transfer protein (CETP). Its primary mechanism of action is the inhibition of CETP, a plasma protein that facilitates the transfer of cholesteryl esters and triglycerides between lipoproteins. By inhibiting CETP, JTT-302 aims to increase high-density lipoprotein cholesterol (HDL-C) levels and favorably modify lipid profiles in patients with dyslipidemia or lipid metabolism disorders. The drug was developed by Japan Tobacco and Akros Pharma for the treatment of dyslipidemia but has not received regulatory approval. Clinical trials reached Phase 2 for this indication[1][3][5].

Other names: CETP inhibitor (oral, dyslipidemia)

Targets

CETP

Beyond the preview

Go deeper on JTT-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JTT-302.

Explore the full profile